AIRLINK 189.52 Decreased By ▼ -0.64 (-0.34%)
BOP 12.77 Decreased By ▼ -0.06 (-0.47%)
CNERGY 7.16 Decreased By ▼ -0.05 (-0.69%)
FCCL 42.12 Decreased By ▼ -1.29 (-2.97%)
FFL 15.54 Increased By ▲ 0.15 (0.97%)
FLYNG 25.19 Decreased By ▼ -1.18 (-4.47%)
HUBC 130.09 Decreased By ▼ -0.52 (-0.4%)
HUMNL 14.32 Increased By ▲ 0.48 (3.47%)
KEL 4.67 Decreased By ▼ -0.04 (-0.85%)
KOSM 6.51 Decreased By ▼ -0.19 (-2.84%)
MLCF 46.94 Decreased By ▼ -2.57 (-5.19%)
OGDC 202.75 Decreased By ▼ -2.06 (-1.01%)
PACE 6.44 Increased By ▲ 0.03 (0.47%)
PAEL 41.14 Increased By ▲ 0.33 (0.81%)
PIAHCLA 17.03 Increased By ▲ 0.18 (1.07%)
PIBTL 8.71 Increased By ▲ 0.02 (0.23%)
POWER 10.70 Decreased By ▼ -0.32 (-2.9%)
PPL 172.21 Decreased By ▼ -2.23 (-1.28%)
PRL 34.77 Increased By ▲ 0.06 (0.17%)
PTC 24.85 Decreased By ▼ -0.14 (-0.56%)
SEARL 96.72 Decreased By ▼ -1.27 (-1.3%)
SILK 1.10 Increased By ▲ 0.01 (0.92%)
SSGC 30.58 Decreased By ▼ -0.52 (-1.67%)
SYM 17.89 Increased By ▲ 0.08 (0.45%)
TELE 8.40 Increased By ▲ 0.10 (1.2%)
TPLP 11.89 Decreased By ▼ -0.29 (-2.38%)
TRG 63.35 Increased By ▲ 1.69 (2.74%)
WAVESAPP 11.63 Decreased By ▼ -0.04 (-0.34%)
WTL 1.50 Increased By ▲ 0.02 (1.35%)
YOUW 4.05 Decreased By ▼ -0.13 (-3.11%)
AIRLINK 189.52 Decreased By ▼ -0.64 (-0.34%)
BOP 12.77 Decreased By ▼ -0.06 (-0.47%)
CNERGY 7.16 Decreased By ▼ -0.05 (-0.69%)
FCCL 42.12 Decreased By ▼ -1.29 (-2.97%)
FFL 15.54 Increased By ▲ 0.15 (0.97%)
FLYNG 25.19 Decreased By ▼ -1.18 (-4.47%)
HUBC 130.09 Decreased By ▼ -0.52 (-0.4%)
HUMNL 14.32 Increased By ▲ 0.48 (3.47%)
KEL 4.67 Decreased By ▼ -0.04 (-0.85%)
KOSM 6.51 Decreased By ▼ -0.19 (-2.84%)
MLCF 46.94 Decreased By ▼ -2.57 (-5.19%)
OGDC 202.75 Decreased By ▼ -2.06 (-1.01%)
PACE 6.44 Increased By ▲ 0.03 (0.47%)
PAEL 41.14 Increased By ▲ 0.33 (0.81%)
PIAHCLA 17.03 Increased By ▲ 0.18 (1.07%)
PIBTL 8.71 Increased By ▲ 0.02 (0.23%)
POWER 10.70 Decreased By ▼ -0.32 (-2.9%)
PPL 172.21 Decreased By ▼ -2.23 (-1.28%)
PRL 34.77 Increased By ▲ 0.06 (0.17%)
PTC 24.85 Decreased By ▼ -0.14 (-0.56%)
SEARL 96.72 Decreased By ▼ -1.27 (-1.3%)
SILK 1.10 Increased By ▲ 0.01 (0.92%)
SSGC 30.58 Decreased By ▼ -0.52 (-1.67%)
SYM 17.89 Increased By ▲ 0.08 (0.45%)
TELE 8.40 Increased By ▲ 0.10 (1.2%)
TPLP 11.89 Decreased By ▼ -0.29 (-2.38%)
TRG 63.35 Increased By ▲ 1.69 (2.74%)
WAVESAPP 11.63 Decreased By ▼ -0.04 (-0.34%)
WTL 1.50 Increased By ▲ 0.02 (1.35%)
YOUW 4.05 Decreased By ▼ -0.13 (-3.11%)
BR100 11,865 Decreased By -96.2 (-0.8%)
BR30 35,321 Decreased By -314 (-0.88%)
KSE100 112,801 Decreased By -938.2 (-0.82%)
KSE30 35,036 Decreased By -291.2 (-0.82%)

NEW DELHI: Indian authorities have halted production of cough syrup at a factory of Maiden Pharmaceuticals, a state minister said on Wednesday, after a WHO report that the medicine may be linked to the deaths of dozens of children in Gambia.

The health minister in Haryana state, Anil Vij, told Reuters partner ANI that authorities inspected a Maiden factory near the town of Sonipat in the state and found 12 violations of good practices.

Production was ordered stopped, Vij said. The WHO said last week that laboratory analysis of four Maiden products - Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup - had “unacceptable” amounts of diethylene glycol and ethylene glycol, which can be toxic and lead to acute kidney injury.

Gambian police, in a preliminary investigation report on Tuesday, said that the deaths of 69 children from acute kidney injury was linked to the cough syrups made in India and imported via a US-based company. It is one of the worst such incidents involving drugs from India, often dubbed a “pharmacy of the world”.

News website Moneycontrol earlier quoted the Haryana drugs controller as saying in a report that Maiden did not perform quality testing of propylene glycol, diethylene glycol and ethylene glycol, while certain batches of propylene glycol did not have the manufacturing and expiry dates.

India awaits WHO information on any cough syrup link to Gambia deaths

Diethylene glycol and ethylene glycol are used in antifreeze and brake fluids and other industrial applications but also as a cheaper alternative in some pharmaceutical products to glycerine, a solvent or thickening agent in many cough syrups.

Maiden executive Naresh Kumar Goyal declined to comment.

He told Reuters last week that the company was trying to find out from its buyer what had happened in Gambia.

Maiden says on its web site it has an annual production capacity of 2.2 million syrup bottles, 600 million capsules, 18 million injections, 300,000 ointment tubes and 1.2 billion tablets at three factories.

It said it sells its products at home and exports to countries in Asia, Africa and Latin America.

The cough syrups had been approved for export only to Gambia, India says, although the WHO says they may have gone elsewhere through informal markets.

India’s health ministry said last week that samples of all four Maiden products that had been exported to Gambia had been sent for testing to a federal laboratory and the results would “guide the further course of action as well as bring clarity on the inputs received/to be received from WHO.”

Health ministry officials and the WHO did not respond to requests for comment.

Comments

Comments are closed.